文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.

作者信息

Schmidt Stefanie, Kunath Frank, Coles Bernadette, Draeger Desiree Louise, Krabbe Laura-Maria, Dersch Rick, Kilian Samuel, Jensen Katrin, Dahm Philipp, Meerpohl Joerg J

机构信息

UroEvidence@Deutsche Gesellschaft für Urologie, Berlin, Germany.

Department of Urology, University Hospital Erlangen, Erlangen, Germany.

出版信息

Investig Clin Urol. 2020 Jul;61(4):349-354. doi: 10.4111/icu.2020.61.4.349. Epub 2020 Jun 29.

DOI:10.4111/icu.2020.61.4.349
PMID:32665991
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7329645/
Abstract
摘要

相似文献

[1]
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.

Investig Clin Urol. 2020-7

[2]
Re: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.

J Urol. 1999-5

[3]
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

BJU Int. 2004-3

[4]
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.

Eur Urol. 2011-7

[5]
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.

Cochrane Database Syst Rev. 2011-5-11

[6]
Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?

Eur Urol. 2009-8

[7]
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.

Eur Urol. 2010-2

[8]
Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.

J Urol. 1998-11

[9]
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

J Urol. 1996-8

[10]
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.

J Urol. 2000-7

引用本文的文献

[1]
A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy.

Int J Mol Sci. 2021-2-1

本文引用的文献

[1]
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Urol Oncol. 1995

[2]
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.

Cancer Treat Rev. 2010-1-15

[3]
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.

Eur Urol. 2009-8

[4]
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.

Arch Ital Urol Androl. 2008-12

[5]
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

Eur Urol. 2007-11

[6]
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.

Eur Urol. 2007-10

[7]
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.

BJU Int. 2007-4

[8]
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Cochrane Database Syst Rev. 2003

[9]
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.

J Urol. 2003-9

[10]
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

J Urol. 2003-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索